These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7507625)

  • 1. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.
    Lewis MG; Elkins WR; McCutchan FE; Benveniste RE; Lai CY; Montefiori DC; Burke DS; Eddy GA; Shafferman A
    Vaccine; 1993 Oct; 11(13):1347-55. PubMed ID: 7507625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
    Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.
    Clements JE; Montelaro RC; Zink MC; Amedee AM; Miller S; Trichel AM; Jagerski B; Hauer D; Martin LN; Bohm RP
    J Virol; 1995 May; 69(5):2737-44. PubMed ID: 7707496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
    Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
    Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
    Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
    AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.
    Miller CJ; McChesney MB; Lü X; Dailey PJ; Chutkowski C; Lu D; Brosio P; Roberts B; Lu Y
    J Virol; 1997 Mar; 71(3):1911-21. PubMed ID: 9032322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
    Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.
    Cole KS; Rowles JL; Jagerski BA; Murphey-Corb M; Unangst T; Clements JE; Robinson J; Wyand MS; Desrosiers RC; Montelaro RC
    J Virol; 1997 Jul; 71(7):5069-79. PubMed ID: 9188572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
    Mossman SP; Bex F; Berglund P; Arthos J; O'Neil SP; Riley D; Maul DH; Bruck C; Momin P; Burny A; Fultz PN; Mullins JI; Liljeström P; Hoover EA
    J Virol; 1996 Mar; 70(3):1953-60. PubMed ID: 8627721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
    J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.
    Glamann J; Burton DR; Parren PW; Ditzel HJ; Kent KA; Arnold C; Montefiori D; Hirsch VM
    J Virol; 1998 Jan; 72(1):585-92. PubMed ID: 9420262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
    Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
    J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys.
    Nguyen QN; Martinez DR; Himes JE; Whitney Edwards R; Han Q; Kumar A; Mangan R; Nicely NI; Xie G; Vandergrift N; Shen X; Pollara J; Permar SR
    Retrovirology; 2018 Mar; 15(1):24. PubMed ID: 29523166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences.
    Shafferman A; Jahrling PB; Benveniste RE; Lewis MG; Phipps TJ; Eden-McCutchan F; Sadoff J; Eddy GA; Burke DS
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7126-30. PubMed ID: 1871125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIV envelope glycoprotein epitopes recognized by antibodies from infected or vaccinated rhesus macaques.
    Torres JV; Anderson DE; Malley A; Banapour B; Axthelm MK; Benjamini E; Gardner MB
    J Med Primatol; 1993; 22(2-3):129-37. PubMed ID: 7692056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of mucosal protection against primary, heterologous simian immunodeficiency virus by a DNA vaccine.
    Fuller DH; Rajakumar PA; Wilson LA; Trichel AM; Fuller JT; Shipley T; Wu MS; Weis K; Rinaldo CR; Haynes JR; Murphey-Corb M
    J Virol; 2002 Apr; 76(7):3309-17. PubMed ID: 11884556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challenge.
    Alpert MD; Rahmberg AR; Neidermyer W; Ng SK; Carville A; Camp JV; Wilson RL; Piatak M; Mansfield KG; Li W; Miller CJ; Lifson JD; Kozlowski PA; Evans DT
    J Virol; 2010 Oct; 84(20):10748-64. PubMed ID: 20702641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys.
    Burns DP; Collignon C; Desrosiers RC
    J Virol; 1993 Jul; 67(7):4104-13. PubMed ID: 8510218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.
    Amos JD; Himes JE; Armand L; Gurley TC; Martinez DR; Colvin L; Beck K; Overman RG; Liao HX; Moody MA; Permar SR
    J Virol; 2015 Sep; 89(18):9485-98. PubMed ID: 26157116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.